Resverlogix Corp.RVX.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · resverlogix.com
Resverlogix Corp. is a late-stage clinical biotechnology company pioneering epigenetic drug development, with its lead candidate apabetalone (RVX-208) being a selective bromodomain and extra-terminal (BET) inhibitor. The company is developing apabetalone for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, and post-COVID conditions, with headquarters in Calgary, Canada.
Key ratios
ROA
-39.4%TTM
2024
-41.3%2023
-44.1%2022
-79.0%
Recent news
Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
Track RVX.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer